Sunday 18 October 2026
Export HURA’s income statement to Excel — free account
TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 70.5%, each against the same quarter a year earlier.
1.76
0.07
−3.83%
Follow HURA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 13,125.00 | 13,650.00 | 5,425.00 | 703.50 | 665.00 | 875.00 | 122.57 | 5.60 | 2.84 | 0.70 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 190,225.00 | 94,325.00 | 31,832.50 | 11,007.50 | 3,412.50 | 5,862.50 | 1,470.00 | 315.00 | 14.60 | 5.50 | |||||
| People | |||||||||||||||
| People | Employees | 4 | 15 | 4 | 2 | 4 | 4 | 3 | 2 | 19 | 22 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| EBT | (9) | (8) | (11) | (8) | (9) | (38) | (23) | (29) | (22) | (30) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (9) | (8) | (11) | (8) | (9) | (38) | (23) | (29) | (22) | (30) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (14,155.40) | (11,728.12) | (9,334.25) | (5,464.85) | (1,527.63) | (2,586.52) | (813.49) | (2.47) | (1.21) | (0.63) | |||||
| Cash flow | (8,576.33) | (11,455.86) | (8,209.08) | (4,218.27) | (1,321.33) | (1,274.32) | (730.90) | (1.01) | (0.79) | (0.58) | |||||
| Capex | (28.00) | (30.00) | (10.50) | 0.00 | 0.00 | (0.34) | 0.00 | (0.11) | 0.00 | 0.00 | |||||
| Free cash flow | (8,604.33) | (11,485.86) | (8,219.58) | (4,218.27) | (1,321.33) | (1,274.66) | (730.90) | (1.11) | (0.79) | (0.58) | |||||
| Book value | 8,098.00 | 9,397.86 | 4,529.33 | 1,311.67 | 43.83 | 714.93 | 422.76 | (0.13) | 0.78 | 0.44 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 19 | 48 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (5) | (8) | (10) | (6) | (8) | (19) | (20) | (12) | (15) | (28) | ||||
| Capex | 0 | 0 | 0 | — | — | 0 | — | (1) | 0 | 0 | |||||
| Free cash flow | (5) | (8) | (10) | (6) | (8) | (19) | (20) | (13) | (15) | (28) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 6 | 7 | 5 | 2 | 0 | 9 | 9 | 1 | 14 | (1) | ||||
| Total debt | — | — | — | — | — | — | — | 2 | — | — | |||||
| Net debt | (6) | (7) | (6) | (4) | (2) | (11) | (12) | (1) | (13) | (4) | |||||
| Shareholders’ equity | 5 | 7 | 5 | 2 | 0 | 11 | 12 | (2) | 15 | 21 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (203.85) | (124.38) | (151.00) | (146.30) | (262.15) | (503.66) | (170.43) | (702.97) | (173.10) | (127.05) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (54,213.07) | (94,508.33) | 0.00 | (569.54) | (114.79) | |||||
| ROE | 646.99 | 1,136.81 | 2,703.29 | 406.38 | 242.16 | 933.62 | 983.79 | 510.31 | (579.24) | (171.92) | |||||
Negative figures in brackets.
Charts ten years each
TuHURA Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $119.2M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| ENGN enGene Therapeutics Inc | $114.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| SEER Seer, Inc. | $113.0M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| FHTX Foghorn Therapeutics Inc. | $112.2M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| Median of peers | $115.2M | — | — | −3.85% | — | −1.55% | 48.55% | (27.39%) |
TuHURA Biosciences, Inc. (HURA) key facts
- TuHURA Biosciences, Inc. (HURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HURA traded at $1.76, a market capitalization of $116.6 million.
- Return on equity was −171.9% and debt-to-equity 0.47.